

# APPENDIX B

## RAM REFERENCE LIST

### Guidelines

American Academy of Pediatrics Committee on Drugs (2012). Clinical Report Neonatal Drug Withdrawal (revised)-Guidance for the Clinician in Rendering Pediatric Care. [http://www.sbp.com.br/pdfs/Clinical\\_Report-Neonatal\\_Drug\\_Withdrawal\\_2012.pdf](http://www.sbp.com.br/pdfs/Clinical_Report-Neonatal_Drug_Withdrawal_2012.pdf)

American Society for Addiction Medicine (2015). National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. May 27, 2015. <http://www.asam.org/docs/default-source/practice-support/guidelines-and-consensus-docs/national-practice-guideline.pdf>

Committee on Health Care for Underserved Women and the American Society for Addiction Medicine, American College of Obstetricians and Gynecologists, (2012, Reaffirmed 2014). Committee Opinion: Opioid Abuse, Dependence and Addiction in Pregnancy. Number 524. <https://www.acog.org/-/media/Committee-Opinions/Committee-on-Health-Care-for-Underserved-Women/co524.pdf?dmc=1&ts=20160302T1440499290>

Reece-Stremtan S, Marinelli KA, and The Academy of Breastfeeding Medicine (2015). The ABM Clinical Protocol #21: Guidelines for Breastfeeding and Substance Use or Substance Use Disorder, Revised 2015. *Breastfeeding Medicine*, 10(3): 135-141.

World Health Organization (2014). Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. WHO Press, Geneva, Switzerland [http://www.who.int/substance\\_abuse/publications/pregnancy\\_guidelines/en/](http://www.who.int/substance_abuse/publications/pregnancy_guidelines/en/)

### Journal Articles

Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. *Pediatrics*. 2006;117(6):e1163-e1169.

Abrahams RR, MacKay-Dunn MH, Nevmerjitskaia V, et al. An evaluation of rooming-in among substance-exposed newborns in British Columbia. *J Obstet Gynaecol Can*. 2010;32:866-871.

Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. *Pediatrics*. 2009;123(5):e849-e856.

Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Ann Intern Med*. 2006;144(2):127-134..

Bada HS, Sithisarn T, Gibson J, et al. Morphine versus clonidine for neonatal abstinence syndrome. *Pediatrics*. 2015;135(2):e383-e391.

## Journal Articles

Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. *Eur Addict Res.* 2009;15:128-134.

Benningfield MM, Dietrich MS, Jones HE, et al. Opioid dependence during pregnancy: relationships of anxiety and depression symptoms to treatment outcomes. *Addiction.* 2012;107(Suppl 1):74-82.

Bogen D, Perel JM, Helsel JC, et al. Pharmacologic evidence to support clinical decision making for peripartum methadone treatment. *Psychopharmacology.* 2013;225(2):441-451.

Buckley V, Razaghi A, Haber P. Predictors of neonatal outcomes amongst a methadone- and/or heroin-dependent population referred to a multidisciplinary perinatal and family drug health service. *Aust N Z J Obstet Gynaecol.* 2013;53(5):464-470.

Coyle M, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. *J Pediatr.* 2002;140:561-564.

Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy: initial patient care and outcome data. *Am J Addict.* 2013;22(3):252-254.

Finnegan LP, Kron RE, Connaughton JF, Emich JP. Assessment and treatment of abstinence in the infant of the drug-dependent mother. *Int J Clin Pharmacol Biopharm.* 1975;12:19-32.

Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. *Addiction.* 2006;101(2):275-281.

Fitzsimons HE, Tuten M, Vaidya V, Jones HE. Mood disorders affect drug treatment success of drug-dependent pregnant women. *J Subst Abuse Treat.* 2007;32(1):19-25.

Gaalema DE, Heil SH, Badger GJ, Metayer JS, Johnston AM. Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone. *Drug Alcohol Depend.* 2013;133(1):266-269.

Gaalema DE, Scott TL, Heil SH, et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. *Addiction.* 2012;107(Suppl 1):53-62.

Haller DL, Knisley JS, Dawson, KS, Schnoll SH. Perinatal substance abusers: psychological and social characteristics. *J Nerv Ment Dis.* 1993;181(8):509-513.

Hamilton R, McGlone L, MacKinnon JR, Russell HC, et al. Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy. *BMJ.* 2010;94:696-700.

## Journal Articles

Hans SL. Developmental consequences of prenatal exposure to methadone. *Ann N Y Acad Sci.* 1989;562:195-207.

Holbrook AM, Baxter JK, Jones HE, et al. Infections and obstetric outcomes in opioid-dependent pregnant women maintained on methadone or buprenorphine. *Addiction.* 2012;107:183-190.

Holbrook AM, Jones HE, Heil SH, et al. Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention. *Drug Alcohol Depend.* 2013;132(1-2):329-334.

Hulse GK, Milne E, English DR, et al. The relationship between maternal use of heroin and methadone and infant birth weight. *Addiction.* 1997;92(11):1571–1579.

Ilett KF, Hackett LP, Gower S, Doherty DA, Hamilton D, Bartu AE. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. *Breastfeeding Med.* 2012;7:269-274.

Jansson LM, Choo R, Velez ML, et al. (2008). Methadone maintenance and breastfeeding in the neonatal period. *Pediatrics.* 2008;121(1):106-114.

Jansson LM, Di Pietro JA, Elko A, Williams EL, Milio L, Velez M. Pregnancies exposed to methadone, methadone and other illicit substances, and poly-drugs without methadone: a comparison of fetal neurobehaviors and infant outcomes. *Drug Alcohol Depend.* 2012;122(3):213-219.

Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. *Neurotoxicol Teratol.* 2011;33(2):240-243.

Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. *Drug Alcohol Depend.* 2003;70:S87-S101.

Johnson RE, Jones HE, Jasinski DR, et al. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. *Drug Alcohol Depend.* 2001;63:97-103.

Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. *Drug Alcohol Depend.* 2014;134:414-417.

Jones HE, Heil SH, Tuten M, et al. Cigarette smoking in opioid-dependent pregnant women: neonatal and maternal outcomes. *Drug Alcohol Depend.* 2013;131(3):271-277.

## Journal Articles

Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid dependent patients: effects on the neonatal abstinence syndrome. *Drug Alcohol Depend.* 2005;79:1-10.

Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. *Am J Addict.* 2006;15:258–259.

Jones HE, Johnson RE, O'Grady KE, Jasinski DR, Tuten M, Milio L. Dosing adjustments in postpartum patients maintained on buprenorphine or methadone. *J Addict Med.* 2008 Jun;2(2):103-107.

Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med.* 2010; 363:2320–2331.

Jones HE, Martin PR, Heil SH, Kaltenbach K, Selby P, Coyle MG, Stine SM, O'Grady KE, Arria AM, Fischer G. Treatment of opioid-dependent pregnant women: clinical and research issues. *J Subst Abuse Treat.* 2008; 35(3),245-259.

Jones HE, O'Grady K, Dahne J, Johnson R, Lemoine L, Milio L, Ordean A, Selby P. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. *Am J Drug Alcohol Abuse.* 2009;35(3):151-156.

Jones HE, O'Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. *Am J Addict.* 2008;17:372-386.

Kahila H, Saisto T, Kivitie-Kallio S, et al. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. *Acta Obstet Gynecol Scand.* 2007;86(2):185-190.

Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. *Drug Alcohol Depend.* 2008;96:69-78.

Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. *Obstet Gynecol Clin North Am.* 1998;25(1):139-151.

Kaltenbach K, Holbrook AM, Coyle MG, et al. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. *Addiction.* 2012;107(Suppl 1):45-52.

Kandall SR, Albin S, Gartner LM, et al. The narcotic-dependent mother: fetal and neonatal consequences. *Early Hum Dev.* 1977;1(2):159-169.

Kelly LE, Rieder MJ, Bridgman-Acker K, et al. Are infants exposed to methadone in utero at an increased risk for mortality? *J Popul Ther Clin Pharmacol.* 2012;19(2):e160-e165.

## Journal Articles

Konijnenberg C, Melinder A. Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development. *Child Neuropsychol.* 2011;17(5):495-519.

Lacroix I., Berrebi A., Garipuy D., et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. *Eur J Clin Pharmacol.* 2011;67:1053-1059.

Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisoehn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. *Drug Alcohol Depend.* 2005;77:31–36.

Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. *Drug Alcohol Depend.* 2006;82(3):250-257.

Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Factors affecting head growth and intellectual function in children of drug addicts. *Pediatrics.* 1985;75:269-274.

Lund IO, Fischer G, Welle-Strand GK, et al. A comparison of buprenorphine + naloxone to buprenorphine and methadone in the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. *Subst Abuse.* 2013;7:61-74.

Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O'Grady KE, Jones HE (2012). Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. *Subst Abuse and Rehabil.* 2012;3:17-25.

Malpas TJ, Darlow BA. Neonatal abstinence syndrome following abrupt cessation of breastfeeding. *NZ Med J.* 1999;112(1080):12-13.

Martin SL, Kilgallen B, Dee DL, Dawson S, Campbell J. Women in a prenatal care/substance abuse treatment program: links between domestic violence and mental health. *Matern Child Health J.* 1998 Jun;2(2):85-94.

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev.* 2009;3:CD002209.

Messinger DS, Bauer CR, Das A, et al. The Maternal Lifestyle Study: cognitive, motor, and behavioral outcomes of cocaine exposed and opiate-exposed infants through three years of age. *Pediatrics.* 2004;113:1677-1685.

Meyer M, Johnston A, Crocker A, Heil S. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. *J Addict Med.* 2015; 9(2): 81-86.

## Journal Articles

Meyer M, Paranya G, Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. *Eur J Pain*. 2010 Oct;14(9):939-943.

Meyer M, Wagner K, Benvenuto A, Plante D, Howard D. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. *Obstet Gynecol*. 2007 Aug;110(2 Pt 1):261-266.

Napolitano A, Theophilopoulos D, Seng SK, Calhoun DA. Pharmacologic management of neonatal abstinence syndrome in a community hospital. *Clin Obstet Gynecol*. 2013;56(1):193-201.

O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. *J Midwifery Womens Health*. 2013;58(4):383-388.

O'Connor AB, O'Brien L, Alto WA, Wong J. Does concurrent in utero exposure to buprenorphine and antidepressant medications influence the course of neonatal abstinence syndrome? *J Matern Fetal Neonatal Med*. 2014;10:1-3.

O'Connor AB, O'Brien L, Alto WA. Are there gender related differences in neonatal abstinence syndrome following exposure to buprenorphine during pregnancy? *J Perinat Med*. 2013;41(5):621-623.

Pace CA, Kaminetzky LB, Winter M, Cheng DM, Saia K, Samet JH, Walley AY. Postpartum changes in methadone maintenance dose. *J Subst Abuse Treat*. 2014 Sep;47(3):229-232.

Parlier AB, Fagan B, Ramage M, Galvin S. Prenatal care, pregnancy outcomes, and postpartum birth control plans among pregnant women with opiate addictions. *South Med J*. 2014;107(11):676-683.

Patel P, Abdel-Latif ME, Hazelton B, et al. Perinatal outcomes of Australian buprenorphine-exposed mothers and their newborn infants. *J Paediatr Child Health*. 2013;49(9):746-753.

Patrick SW, Schumacher RE, Bennyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures, United States, 2000-2009. *JAMA*. 2012;307(18):1934-1940.

Patrick, SW, J Dudley, Martin PR, et al. Prescription opioid epidemic and infant outcomes. *Pediatrics*. 2015;135(5):842-851.

Rosen TS, Johnson HL. Children of methadone-maintained mothers: follow-up to 18 months of age. *J Pediatrics*. 1982;101(2):192-196.

## Journal Articles

Ruwanpathirana R, Abdel-Latif ME, Burns L, et al. Prematurity reduces the severity and need for treatment of neonatal abstinence syndrome. *Acta Paediatr.* 2015;104(5):e188-e194.

Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. *Addiction.* 2012;107(1):36-44.

Sarfi M, Sundet JM, Waal H. Maternal stress and behavioral adaptation in methadone- or buprenorphine-exposed toddlers. *Infant Behav Dev.* 2013;36(4):707-716.

Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in US neonatal ICUs. *NEJM.* 2015;372(22):2118-2126.

Unger AS, Martin PR, Kaltenbach K, et al. Clinical characteristics of Central European and North American samples of pregnant women screened for opioid agonist treatment. *Eur Addict Res.* 2010;16(2):99-107.

Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. *JAMA.* 2013;309(17):1821-1827.

Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a national cohort study of opioid-agonist treatment of pregnant women in Norway from 1996 to 2009. *Drug Alcohol Depend.* 2013;127(1-3):200-206.

Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. *Obstet Gynecol.* 2015;125(2):363-368.